PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation
Authors:
Open Access
- 29 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 668247
Abstract
Basal cell carcinoma (BCC) is a locally invasive epithelial cancer that is primarily driven by the Hedgehog (HH) pathway. Advanced BCCs are a critical subset of BCCs that frequently acquire resistance to Smoothened (SMO) inhibitors and identifying pathways that bypass SMO could provide alternative treatments for patients with advanced or metastatic BCC. Here, we use a combination of RNA-sequencing analysis of advanced human BCC tumor-normal pairs and immunostaining of human and mouse BCC samples to identify a PI3K pathway expression signature in BCC. Pharmacological inhibition of PI3K activity in BCC cells significantly reduces cell proliferation and HH signaling. However, treatment of Ptch1fl/fl; Gli1-CreERT2 mouse BCCs with the PI3K inhibitor BKM120 results in a reduction of tumor cell growth with no significant effect on HH signaling. Downstream PI3K components aPKC and Akt1 showed a reduction in active protein, whereas their substrate, cyclin-dependent kinase inhibitor p21, showed a concomitant increase in protein stability. Our results suggest that PI3K promotes BCC tumor growth by kinase-induced p21 degradation without altering HH signaling.Keywords
Funding Information
- National Institutes of Health
- American Cancer Society
This publication has 67 references indexed in Scilit:
- Everolimus for Compassionate Use in Multiple Basal Cell CarcinomasCase Reports in Dermatological Medicine, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- The Crosstalk of mTOR/S6K1 and Hedgehog PathwaysCancer Cell, 2012
- A mechanism for vertebrate Hedgehog signaling: recruitment to cilia and dissociation of SuFu–Gli protein complexesJournal of Cell Biology, 2010
- Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in MedulloblastomaScience Translational Medicine, 2010
- The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteinsGenes & Development, 2010
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2009
- KEA: kinase enrichment analysisBioinformatics, 2009
- Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signalingNature Genetics, 2008
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006